Is Switzerland Becoming Europe's Biotech Capital?

Biogen Idec's decision to move its international headquarters from Paris to Switzerland reflects the growing size, and changing structure, of its international business. It also increases Switzerland's already strong allure as Europe's friendliest biotech hub.

Melanie Senior

When Biogen Idec Inc. 's flagship multiple sclerosis drug interferon beta (Avonex) was approved in Europe in 1997, the...

More from Global Vision

More from In Vivo